Company Filing History:
Years Active: 2024-2025
Title: Matthew Drever: Innovator in Antibody and Cell Therapy Technologies
Introduction
Matthew Drever is a prominent inventor based in Concord, CA (US). He has made significant contributions to the fields of antibody and cell therapy technologies. With a total of 3 patents, his work focuses on innovative solutions for medical treatments.
Latest Patents
Drever's latest patents include groundbreaking advancements in TACI binding molecules. These patents provide antibodies, fragments thereof, chimeric antigen receptors (CARs), and T cell receptors (TCRs) that comprise one or more of the dual TACI-BCMA binding domains. The patents also detail compositions, cells, and cell therapies that utilize these innovations, along with methods of treatment. Another notable patent involves systems targeting PSMA and CA9. This patent outlines antibodies and chimeric priming receptors that bind PSMA, as well as systems of chimeric priming receptors that bind CA9. It also includes cells expressing these systems and methods of use.
Career Highlights
Throughout his career, Matthew Drever has worked with leading companies in the biotechnology sector. He has been associated with Kite Pharma, Inc. and Arsenal Biosciences, Inc., where he has contributed to the development of cutting-edge therapies.
Collaborations
Drever has collaborated with notable professionals in his field, including Angela Boroughs and Levi Gray-Rupp. These collaborations have further enhanced his innovative work in antibody and cell therapy technologies.
Conclusion
Matthew Drever's contributions to the field of biotechnology through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for advancements in medical treatments and therapies.